|Issuer:||SIGILON THERAPEUTICS, INC. (SGTX)|
|Original Submission Date:|
COLE DOUGLAS G.
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600 CAMBRIDGE, MA 02142
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||0.7632||2022-05-26||deemed execution date||A||8,888 (a)||2032-05-25||common stock 8,888||$0.76||8,888||direct|
|f1||the option was issued pursuant to the sigilon therapeutics, inc. 2020 equity incentive plan. the option will vest as to 100% on may 26, 2023|